



SPARSH BIO-TECH PVT. LTD.

PHARMACEUTICAL MANUFACTURER & EXPORTERS
PLOT NO.1, SURVEY NO. 242/243/244, LAKHABAVAD, JAMNAGAR – 361 006 (INDIA)

1.6. PRODUCT INFORMATION

1.6.1. PRESCRIBING INFORMATION

(SUMMARY OF PRODUCTS CHARACTERISTICS)

1 Product Name

Brand Name : SPAMOX ORAL SUSPENSION

INN or Generic Name : Amoxicillin Oral Suspension B.P.

Dosage form : Powder For Oral Suspension (Dry Syrup)

Strength : After Reconstitution each 5 ml contains:
Amoxicillin Trihydrate B.P. equivalent to Amoxicillin 125 mg

**2. Qualitative and quantitative Composition**

Sr. No.	Ingredients	Specifi- cation	Label claim	Overages (%)	Actual Quantity per 5 ml (in mg)	% of doses per 5 ml	Function
1	Amoxicillin Trihydrate equivalent to Amoxicillin	BP 2018	145mg ≅ 125mg	8%	156.600	15.66	Active
2	Sodium Benzoate	BP 2018		--	2.503	0.25	Preservative
3	Xanthan gum	BP 2018		--	10.00	1.00	Suspending Agent
4	Sodium citrate	BP 2018		--	8.333	0.83	Buffer
5	Citric acid (Anhydrous)	BP 2018		--	2.085	0.21	Buffer
6	Colloidal silicon Dioxide	BP 2018		--	22.059	2.21	Lubricant
7	Sugar (Pulverized)	BP 2018		--	767.641	76.76	Sweetening agent
8	Flavour Pineapple Dry Mix.	IHS		--	5.556	0.56	Flavouring agent
9	Colour Sunset Yellow FCF	IHS		--	0.222	0.02	Colouring agent
10	Purified talc	BP 2018		--	25.00	2.50	Lubricant
TOTAL					1000.00	100 %	

Where,

BP 2018 = British Pharmacopoeia 2018

IHS = In-House Specifications

3. PHARMACEUTICAL FORM

POWDER FOR ORAL SUSPENSION (Dry Syrup)

4. Clinical particulars**4.1 Therapeutic indications**

Amoxicillin is a broad spectrum antibiotic indicated for the treatment of commonly occurring bacterial infections such as:

Respiratory tract infections caused by microorganisms such as non-penicillinase producing *H. influenzae*, staphylococci, and streptococci, including *Streptococcus pneumoniae*.

Gastrointestinal tract Infections caused by microorganisms such as *Shigella*, *S. typhosa*, *Salmonella*, *E.Coli*, *P. mirabilis* and enterococci. Meningitis *N. meningitidis*.



Genitourinary tract infections caused by microorganisms including Gonorrhoea, E. Coli, P. mirabilis, enterococci, Shigella, S. typhosa, N. gonorrhoea, Salmonella and other non penicillinase producing microorganisms.

Other bacterial infections such as:

Otitis media

Acute and chronic bronchitis

Chronic bronchial sepsis

Lobar and bronchopneumonia

Cystitis, urethritis, pyelonephritis

Bacteriuria in pregnancy

Gynaecological infections including puerperal sepsis and septic abortion

Gonorrhoea

Peritonitis

Intra-abdominal sepsis

Septicaemia

Bacterial endocarditis

Typhoid and paratyphoid fever

Skin and soft tissue infections

Dental abscess (as an adjunct to surgical management)

Helicobacter pylori eradication in peptic (duodenal and gastric) ulcer disease.

In children with urinary tract infection the need for investigation should be considered.

Prophylaxis of endocarditis: Amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis.

4.2) POSOLOGY AND METHOD OF ADMINISTRATION:

Route of administration: oral use

Amoxicillin capsules, tablets & oral suspension may be given without regards to meals. The usual dosage regimen of amoxicillin is 250 to 500 mg three times a day. For children half of the adult dose may be used. Some infections may be treated with special dosage regimens given below:

maximum recommended oral dosage 6 g daily in divided doses: A dosage of 3 g twice daily is recommended in appropriate cases for the treatment of severe or recurrent purulent infection of the respiratory tract.

- a) Respiratory tract infections - 3g twice a day
- b) Acute urinary tract infections - 3g repeated once 12 hours later.
- c) Gonorrhoea - 3g single dose.



- d) Dental Abscess - 3g repeated once 8 hours later.
- e) Prophylaxis of endocarditis - Single 3g dose one hour before dental procedure from which bacteraemia may arise. Repeated 6 hours later if necessary.

4.3) CONTRAINDICATION:

A history of allergic reaction to any of the penicillin is a contraindication. The use of this drug is contraindicated in individuals with a history of previous hypersensitivity reaction to any of the penicillins. Amoxicillin is also contraindicated in infections caused by penicillinase producing organisms.

4.4) SPECIAL WARNINGS AND PRECAUTIONS FOR USE:**Warnings**

Serious and occasionally fatal hypersensitivity reactions have been reported in patients on parenteral penicillin therapy. These reactions may occur with oral penicillin particularly in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before therapy with any penicillin careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs, appropriate therapy should be instituted and discontinuance of amoxicillin therapy considered. Serious anaphylactic reactions require immediate emergency treatment with Epinephrine, oxygen, intravenous steroids and air way management including intubations should also be administered as indicated.

Precautions

As with any potent drug periodic assessment of renal, hepatic and hemaropoietic function should be made during prolonged therapy. The possibility of super infections with mycotic or bacterial pathogens should be kept in mind during therapy.

Before initiating therapy with amoxicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporin' s, or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted.

If super infections occur (usually involving Entero-bacter, pseudomonas or Candida), the drug should be discontinued and/or appropriate therapy instituted.



SPARSH BIO-TECH PVT. LTD.

PHARMACEUTICAL MANUFACTURER & EXPORTERS
PLOT NO.1, SURVEY NO. 242/243/244, LAKHABAVAD, JAMNAGAR – 361 006 (INDIA)

4.5) INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION:

Probenecid decreases the renal tubular secretion of Amoxicillin, concurrent use of Amoxicillin and Probenecid may result in increased and prolonged blood levels of amoxicillin.

Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere with the bactericidal effects of amoxicillin. This has been demonstrated invitro, however, the clinical significance of this interaction is not well documented.

Amoxicillin show possible antagonism effects with Demeclocycline, Doxycycline, Methacycline, Minocycline, Oxytetracycline, Rolitetracycline and Tetracycline.

This anti-infectious agent could decrease the effect of the oral contraceptive like Ethinyl Estradiol and Mestranol.

Amoxicillin increases the effect and toxicity of methotrexate.

Pseudomembranous colitis has been reported with nearly all-antibacterial agents, including amoxicillin, any may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by clostridium difficile is a primary cause of 'antibiotic-associated colitis'. After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measure should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment and with antibacterial drug clinically effective against Clostridium difficile colitis.

4.6) PREGNANCY AND LACTATION:

PREGNANCY

Categ



Amoxicillin may be given during lactation. With the exception of the risk of sensitisation associated with the excretion of trace quantities of amoxicillin in breast milk, there are no known detrimental effects for the breast-fed infant.

4.7) EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

No effect on the above. No sedation / drowsiness has been reported.

4.8) UNDESIRABLE EFFECTS:

As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever or urticaria. The following adverse reactions have been reported as associated with the use of penicillin.

Gastrointestinal : Nausea, vomiting and diarrhoea.

Hypersensitivity: Erythematous maculopapular rashes and urticaria have been reported.

Note: Urticaria, other skin rashes and serum sickness-like reactions, may be controlled with antihistamines and, if necessary systemic corticosteroids. Whenever such reactions occur Amoxicillin should be continued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to Amoxicillin therapy.

Liver: A moderate use in serum glutamic oxaloacetic transaminases (SGOT) has been noted but the significance of this finding is unknown.

Central Nervous System: Reversible hypersensitivity, agitation, anxiety, insomnia, confusion, behavioral changes and/or dizziness have reported rarely.

Cytopenic purpura eosinophilia, leukopenia have been reported during therapy with the penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

4.9) OVERDOSE:

In case of overdose, discontinue medication, treat symptomatically and institute supportive measures as required. In patients with renal function impairment, Amoxicillin class antibiotics can be removed by haemodialysis but not by peritoneal dialysis.

If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed.

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin. Renal impairment appears to be reversible with



cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin.

Problems of overdose with amoxicillin are unlikely to occur. If encountered, gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically with attention to the water/electrolyte balance.

During administration of high doses of amoxicillin, adequate fluid intake and urinary output must be maintained to minimize the possibility of amoxicillin crystalluria. Amoxicillin can be removed from the circulation by haemodialysis.

5) PHARMACOLOGICAL PROPERTIES

5.1) PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antibiotics

ATC Code : J01CA04

ANATOMIC THERAPEUTIC CHEMICAL AND FORENSIC CLASSIFICATION:

J	GENERAL ANTIINFECTIVES, SYSTEMIC
J01	SYSTEMIC ANTIBIOTICS
C	PENICILLINS WITH INCREASES EFFECT ON GRAM-NEGATIVE BACILLI

MECHANISM OF ACTION

This drug acts by inhibiting the synthesis of bacterial cell walls by binding to one or more of the penicillin-binding proteins (PBPs). It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell walls of both Gram-positive and Gram-negative bacteria.

It has two ionizable groups in the physiological range (the amino group in alpha-position to the amide carbonyl group and the carboxyl group).

Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall thus inhibiting cell wall biosynthesis resulting in bacterial lysis.

**PHARMACODYNAMICS**

Amoxicillin is a broad spectrum antibiotic.

It is rapidly bactericidal and possesses the safety profile of a penicillin.

The wide range of organisms sensitive to the bactericidal action of Amoxicillin.

It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other beta-lactam antibiotics.

Amoxicillin exerts bactericidal action against susceptible organisms during the stage of active multiplication.

5.2) PHARMACOKINETIC PROPERTIES**Absorption**

Amoxicillin is stable in the presence of gastric acid and may be given without regards to meals. It is rapidly absorbed after oral administration.

Distribution

Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid, except when meninges are inflamed. The half life of amoxicillin is 61.2 minutes.

In blood serum, amoxicillin is approximately 20% protein bound as compared to 60% of penicillin G. Orally administered doses of 250mg and 500mg amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5mcg/ml to 5.0 mcg/ml and 5.5 mcg/ml to 7.5mcg/ml respectively.

Detectable serum levels are observed upto 8 hours after and oral administered dose of Amoxicillin. Following a 1g dose and utilizing a special skin window technique to determine levels of antibiotic, it was noted that therapeutic levels were found in the intestinal fluids.

Metabolism

Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins

Converted to a limited extent to penicilloic acid.

Excretion

Most of the amoxicillin is excreted unchanged in urine; excretion can be delayed by concurrent administration of probenecid.

Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within six to eight hours by glomerular filtration and tubular secretion.



Excreted via the faeces. May be removed by haemodialysis.

MICROBIOLOGY:

Amoxicillin is similar to Ampicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopolypeptides. Amoxicillin has been shown to be active against most strains of the following microorganisms, both in-vitro and in clinical infections as describe INDICATION.

Aerobic Gram-positive Microorganisms:

Enterococcus faecalis.

Staphylococcus spp. (lactamase-negative strains only)

Streptococcus pneumoniae.

Streptococcus spp (and haemolytic strains only)

Streptococcus pyogenes

Streptococcus viridans

Staphylococcus aureus (penicillin-sensitive strains only)

Corynebacterium species

Bacillus anthracis

Listeria monocytogenes

Staphylococci, which are susceptible to Amoxicillin but resistant to methicillin/oxacillin, should be considered as resistant to amoxicillin.

Aerobic Gram-negative Microorganisms:

Escherichia coli (lactamase- negative strains only)

Haemophilus Influenzae (lactamase- negative strains only)

Neisseria gonorrhoeae (lactamase- negative strains only)

Proteus mirabilis (lactamase- negative strains only)

Helicobacter pylori.

Salmonella species

Shigella species

Bordetella pertussis

Brucella species



Neisseria meningitidis

Vibrio cholerae

Pasteurella septica

Anaerobic Microorganisms:

Clostridium species

5.3) PRECLINICAL SAFETY DATA

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction.

6 Pharmaceutical particulars

6.1 List of excipients

- 1 Sodium Benzoate
- 2 Xanthan gum
- 3 Sodium citrate
- 4 Citric acid (Anhydrous)
- 5 Colloidal silicon Dioxide
- 6 Sugar (Pulverized)
- 7 Flavour Pineapple Dry Mix.
- 8 Colour Sunset Yellow FCF
- 9 Purified talc

6.2 Incompatibilities:

It is observed that Amoxicillin Trihydrate is a stable molecule and exhibits good amount of compatibility with the above listed excipients tested for three month at 40°C / 75% RH. Hence these excipients are not expected to cause any stability problems in the formulation.

6.3 Shelf life

2 Years

6.4 Special precautions for storage:

Keep container tightly closed, Store in dry place, Temperature not exceeding 25°C.

Keep all medicines out of sight & reach of Children.



SPARSH BIO-TECH PVT. LTD.

PHARMACEUTICAL MANUFACTURER & EXPORTERS

PLOT NO.1, SURVEY NO. 242/243/244, LAKHABAVAD, JAMNAGAR – 361 006 (INDIA)

6.5 Nature and contents of container:

100 ml Amber Coloured Glass Bottle packed in a carton with leaflet & measuring cup

6.6 Special precautions for disposal

No special requirements

7. Marketing authorization holder and manufacturing site addresses.

SPARSH BIO-TECH PVT. LTD.

Plot No. 1, Survey No. 242/243/244, Village lakhabavad, Jamnagar – 361006, India.

8. Marketing authorization Number

Product license Number G/1174

9. Date of first authorization/renewal of the authorization

10. Date of revision of the text

11. Dosimetry : Not Applicable

12 Instructions for Preparation of Radio pharmaceuticals : Not Applicable